Pettengell R, Davies A J, Harvey V J
Oncology Department, Auckland Hospital.
N Z Med J. 1991 Jul 10;104(915):284-5.
Seventy-one patients receiving prolonged outpatient chemotherapy for solid tumours had a totally implanted venous access system inserted (Port-A-Cath--Pharmacia). These remained in situ for a mean of 278 days. In 98.6% of patients the catheter functioned throughout treatment. This high reliability reflects low rates of sepsis (11%) and occlusion (1.4%). Six catheters were removed because of complications; for sepsis (2), catheter occlusion (1), erosion (2), and wound dehiscence (1). An implanted system may be more economical than external exiting systems for patients requiring a catheter for longer than two months despite a high capital cost, because of lower costs during use. The Port-A-Cath is safe, reliable and acceptable to patients.
71例接受实体瘤长期门诊化疗的患者植入了完全植入式静脉通路系统(Port-A-Cath——法玛西亚公司产品)。这些系统平均在位278天。98.6%的患者导管在整个治疗过程中功能良好。这种高可靠性反映出败血症发生率低(11%)和堵塞发生率低(1.4%)。6根导管因并发症被拔除;原因分别为败血症(2例)、导管堵塞(1例)、侵蚀(2例)和伤口裂开(1例)。对于需要使用导管超过两个月的患者,尽管植入式系统的初始成本较高,但由于使用期间成本较低,可能比外部引出式系统更经济。Port-A-Cath安全、可靠且患者可接受。